In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors approved a reduction in the Company’s workforce, impacting 87 employees, which occurred during May and June 2024. The Company incurred costs related to employee termination benefits and other costs associated with the restructuring mainly during the second quarter of 2024, with the remainder of the costs to be incurred through 2025. These amounts are recorded as restructuring and other related charges within our consolidated statements of operations and comprehensive loss as they are incurred. For the year ended December 31, 2025, restructuring and other related charges were $1.5 million, which consisted of $1.2 million of severance costs and $0.3 million of retention costs. For the year ended December 31, 2024, restructuring and other related charges were $10.9 million, which consisted of $6.7 million of severance costs, $3.2 million of retention costs, and $1.0 million of other costs.

Restructuring liability activities during the years ended December 31, 2025 consist of the following (in thousands):


	Severance Costs			Retention Costs			Other Costs			Total Restructuring
Balance at December 31, 2023	$	—		$	—		$	—		$	—
Accruals		6,713			3,174			1,009			10,896
Cash payments		(3,953	)		(1,596	)		(1,000	)		(6,549	)
Balance at December 31, 2024		2,760			1,578			9			4,347
Accruals		1,189			280			—			1,469
Cash payments		(683	)		(1,858	)		(9	)		(2,550	)
Balance at December 31, 2025	$	3,266		$	—		$	—		$	3,266